Overview of genotoxic impurities in pharmaceutical development

Area of Science:

• Pharmaceutical Synthesis
• Toxicology
• Regulatory Science

Background:

• Recent European and US regulations mandate robust control of genotoxic impurities in new drug applications.
• Genotoxic impurities pose unique challenges compared to standard International Conference on Harmonisation (ICH) Q3A/Q3B guidances.
• Standard genotoxicity tests for drug substances may not adequately assess the safety of specific genotoxic impurities.

Purpose of the Study:

• To outline current strategies for managing genotoxic impurities in pharmaceutical manufacturing.
• To discuss recent regulatory advancements and industry best practices for impurity control.
• To provide practical examples of impurity introduction and management in drug synthesis.

Main Methods:

• Review of current regulatory requirements in Europe and the United States.
• Application of the threshold of toxicological concern (TTC) as a risk management framework.
• Discussion of industry case studies illustrating impurity management.
• Incorporation of updated regulatory concepts like the 'staged threshold of toxicological concern' for short-term drug administration.

Main Results:

• Sponsors must develop specific processes to control genotoxic impurity risks.
• The TTC serves as a default risk management approach for genotoxic impurities.
• Industry examples demonstrate practical implementation of impurity control measures.
• The 'staged TTC' offers a tailored approach for impurities in short-duration therapies.

Conclusions:

• Effective management of genotoxic impurities is essential for pharmaceutical development and regulatory compliance.
• The TTC and its variations provide a structured approach to assessing and controlling risks associated with genotoxic impurities.
• Industry collaboration and adherence to evolving regulatory guidance are key to ensuring drug safety.